ReGEN Biomedical

Revolutionizing the production of functional tissues

Access Document

Access to the ReGEN Biomedical Innovation Cluster

1. Purpose

ReGEN Biomedical B.V. operates as part of the RegMed XB Pilot Factory and provides specialised infrastructure, expertise and innovation-cluster activities for regenerative medicine, tissue engineering, automation, scale-up, analysis and quality-control related workflows.

This document describes the general principles under which external organisations may request access to ReGEN's facilities, expertise, services and innovation-cluster activities.

2. General principle: open, transparent and non-discriminatory access

Access to the ReGEN Biomedical innovation cluster may be requested by multiple types of external users, including companies, knowledge institutions, start-ups, consortia and ecosystem partners.

Requests are assessed using objective and transparent principles. Access is not limited to shareholders, affiliates, existing partners or pre-selected organisations.

Access is not automatic and does not create legal entitlement. Any access remains subject to availability, technical feasibility, safety, quality, confidentiality, regulatory considerations and written agreement.

3. Scope of access

Access may relate to one or more of the following activities or services:

- use of ReGEN facilities, laboratories, equipment or automated platforms;
- process development for microtissues, spheroids, organoids or related cell-based systems;
- automation, scale-up, analytical and quality-control support;
- feasibility studies, pilot projects, proof-of-concept work or technical project support;
- workshops, demonstrations, training or knowledge-sharing activities;
- business, technical or project-development support within the regenerative medicine ecosystem.

4. Request and assessment process

External parties can request access by contacting ReGEN through the contact details published on ReGEN's website. ReGEN may ask the requesting party to provide sufficient information about the organisation, proposed activity, intended use, desired planning, technical scope and relevant safety or quality requirements.

Each request is assessed case by case. ReGEN may approve, decline, postpone or limit access where objectively justified.

Assessment criteria may include:

- fit with ReGEN's expertise, facilities and strategic scope;
- technical feasibility and maturity of the request;
- available capacity, personnel, equipment and materials;
- safety, quality, confidentiality, IP and regulatory considerations;
- commercial and contractual feasibility;
- contribution to innovation, collaboration and ecosystem development.

5. Pricing and cost principles

Fees for the use of ReGEN facilities, services and innovation-cluster activities are based on market-conform rates or reflect the underlying costs of providing access. Relevant cost elements may include personnel, equipment use, materials, facility costs, operational costs and third-party costs.

Any prices, examples or cost indications communicated publicly or during preliminary discussions are non-binding and indicative only. Final pricing is project-specific and will be agreed in writing before any work starts.

Preferential access or specific conditions, if any, must be objectively justified, proportionate and documented. Existing relationships with ReGEN do not automatically create preferential access.

6. Safeguards and limitations

Topic	Safeguard
No automatic access	Publication of this document does not guarantee access. Access depends on capacity, technical feasibility, safety, quality, confidentiality, regulatory requirements and written agreement.
No binding offer	This document is not an offer, quotation or commitment to provide services. Any project or service must be agreed separately in writing.
No subsidy entitlement	Access to the innovation cluster does not create an entitlement to public funding, article 25/SILO project selection or subsidy support.
No compliance guarantee	This document does not constitute legal, tax, subsidy or state-aid advice and does not certify compliance by any third party.
Operational control	ReGEN may restrict, supervise, postpone or refuse access where required for safety, quality, security, capacity or confidentiality reasons.
Confidentiality and IP	Confidentiality, publication rights, background IP, foreground IP and data use will be addressed in the relevant written agreement where applicable.

7. Safety, quality and facility rules

All users, visitors and project partners must comply with ReGEN's applicable facility, safety, quality, confidentiality, security and visitor procedures.

This may include visitor registration, supervised access, restrictions for controlled areas, compliance with health and safety instructions, use of appropriate training or documentation, and adherence to applicable laboratory and quality procedures.

8. Separation from article 25 and article 26 activities

This access document relates primarily to access to ReGEN's innovation-cluster activities under article 27 AGVV.

Where a project concerns R&D support or funding under article 25 AGVV (known as the "*ReGEN Biomedical Development Program*"), separate project-selection, funding, documentation, assessment and reporting requirements may apply. Where activities relate to research infrastructure under article 26 AGVV, separate infrastructure-related requirements may apply.

ReGEN maintains administrative separation between article 25, article 26 and article 27 activities, costs and revenues. Advantages or support under one activity are not intended to be passed on to other activities unless expressly permitted and documented.

Important distinction

- Article 27 access to the innovation cluster is not the same as article 25/SILO funding via the "ReGEN Biomedical Development Program".
- Participation in publicly funded R&D projects is governed by the relevant call conditions, assessment framework, state-aid requirements and written project documentation.
- This document should not be read as a promise to finance, select or approve any R&D project.

9. Documentation and audit trail

ReGEN may retain documentation of access requests, assessments, offers, agreements, usage, invoices, cost calculations, safety checks and relevant correspondence for administrative, contractual, audit, subsidy, quality or legal purposes.

Where access is refused, postponed or limited, ReGEN may document the objective reason for that decision.

10. Contact

ReGEN Biomedical B.V.
Graanmolen 20
6229 PA Maastricht
The Netherlands
E-mail: info@regenbiomedical.com
Website: www.regenbiomedical.com

11. Non-binding nature of this document

This access document is intended to describe the general principles under which external organisations may request access to the ReGEN Biomedical innovation cluster. It does not constitute an offer, quotation, guarantee of access, subsidy commitment or legal entitlement.

ReGEN Biomedical reserves the right to update this document and to refuse, postpone or limit access where objectively justified. Any access, service or project will only become binding after written agreement by duly authorised representatives of the relevant parties.